Browse > Article
http://dx.doi.org/10.4062/biomolther.2012.20.1.001

Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments  

Rubio, Maria D. (Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham)
Drummond, Jana B. (Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham)
Meador-Woodruff, James H. (Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham)
Publication Information
Biomolecules & Therapeutics / v.20, no.1, 2012 , pp. 1-18 More about this Journal
Abstract
Schizophrenia is a devastating psychiatric illness that afflicts 1% of the population worldwide, resulting in substantial impact to patients, their families, and health care delivery systems. For many years, schizophrenia has been felt to be associated with dysregulated dopaminergic neurotransmission as a key feature of the pathophysiology of the illness. Although numerous studies point to dopaminergic abnormalities in schizophrenia, dopamine dysfunction cannot completely account for all of the symptoms seen in schizophrenia, and dopamine-based treatments are often inadequate and can be associated with serious side effects. More recently, converging lines of evidence have suggested that there are abnormalities of glutamate transmission in schizophrenia. Glutamatergic neurotransmission involves numerous molecules that facilitate glutamate release, receptor activation, glutamate reuptake, and other synaptic activities. Evidence for glutamatergic abnormalities in schizophrenia primarily has implicated the NMDA and AMPA subtypes of the glutamate receptor. The expression of these receptors and other molecules associated with glutamate neurotransmission has been systematically studied in the brain in schizophrenia. These studies have generally revealed region- and molecule-specifi c changes in glutamate receptor transcript and protein expression in this illness. Given that glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, recent drug development efforts have targeted the glutamate system. Much effort to date has focused on modulation of the NMDA receptor, although more recently other glutamate receptors and transporters have been the targets of drug development. These efforts have been promising thus far, and ongoing efforts to develop additional drugs that modulate glutamatergic neurotransmission are underway that may hold the potential for novel classes of more effective treatments for this serious psychiatric illness.
Keywords
Ionotropic; Metabotropic; Antipsychotics; Modulators; Accessory proteins;
Citations & Related Records

Times Cited By Web Of Science : 1  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Clinton, SM, Haroutunian, V and Meador-Woodruff, JH (2006) Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J. Neurochem. 98, 1114-1125.   DOI   ScienceOn
2 Clinton, S. M. and Meador-Woodruff, J. H. (2004) Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology 29, 1353-1362.   DOI   ScienceOn
3 Collingridge, G. L., Olsen, R. W., Peters, J. and Spedding, M. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology 56, 2-5.   DOI   ScienceOn
4 Coombs, I. D. and Cull-Candy, S. G. (2009) Transmembrane AMPA receptor regulatory proteins and AMPA receptor function in the cerebellum. Neuroscience 162, 656-665.   DOI   ScienceOn
5 Copits, B. A, Robbins, J. S., Frausto, S. and Swanson, G. T. (2011) Synaptic targeting and functional modulation of GluK1 kainate receptors by the auxiliary neuropilin and tolloid-like (NETO) proteins. J. Neurosci. 31, 7334-7340.   DOI   ScienceOn
6 Corti, C., Crepaldi, L., Mion, S., Roth, A. L., Xuereb, J. H. and Ferraguti, F. (2007) Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry 62, 747-755.   DOI   ScienceOn
7 Corti, C., Xuereb, J. H., Crepaldi, L., Corsi, M., Michielin, F. and Ferraguti, F. (2011) Altered levels of glutamatergic receptors and $Na^+/K^+$ ATPase-alpha1 in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 128, 7-14.   DOI   ScienceOn
8 Cousins, S. L., Papadakis, M., Rutter, A. R. and Stephenson, F. A. (2008) Differential interaction of NMDA receptor subtypes with the post-synaptic density-95 family of membrane associated guanylate kinase proteins. J. Neurochem. 104, 903-913.   DOI   ScienceOn
9 Coyle, J. T. (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3, 241-253.   DOI   ScienceOn
10 Rosse, R. B., Schwartz, B. L., Leighton, M. P., Davis, R. E. and Deutsch, S. I. (1990) An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin. Neuropharmacol. 13, 348-354.   DOI   ScienceOn
11 Rothstein, J. D., Martin, L., Levey, A. I., Dykes-Hoberg, M., Jin, L., Wu, D., Nash, N. and Kuncl, R. W. (1994) Localization of neuronal and glial glutamate transporters. Neuron 13, 713-725.   DOI   ScienceOn
12 Sala, C. and Sheng, M. (1999) The fyn art of N-methyl-D-aspartate receptor phosphorylation. Proc. Natl. Acad. Sci. USA 96, 335-337.   DOI   ScienceOn
13 Sans, N., Prybylowski, K., Petralia, R. S., Chang, K., Wang, Y. X., Racca, C., Vicini, S. and Wenthold, R. J. (2003) NMDA receptor traffi cking through an interaction between PDZ proteins and the exocyst complex. Nat. Cell Biol. 5, 520-530.   DOI   ScienceOn
14 Sans, N., Wang, P. Y., Du, Q., Petralia, R. S., Wang, Y. X., Nakka, S., Blumer, J. B., Macara, I. G. and Wenthold, R. J. (2005) mPins modulates PSD-95 and SAP102 traffi cking and infl uences NMDA receptor surface expression. Nat. Cell Biol. 7, 1179-1190.   DOI   ScienceOn
15 Scarr, E., Beneyto, M., Meador-Woodruff, J. H. and Dean, B. (2005) Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 30, 1521-1531.   DOI   ScienceOn
16 Schiffer, H. H., Swanson, G. T. and Heinemann, S. F. (1997) Rat GluR7 and a carboxy-terminal splice variant, GluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate. Neuron 19, 1141-1146.   DOI   ScienceOn
17 Schmitt, A., Koschel, J., Zink, M., Bauer, M., Sommer, C., Frank, J., Treutlein, J., Schulze, T., Schneider-Axmann, T., Parlapani, E., Rietschel, M., Falkai, P. and Henn, F. A. (2010) Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 260, 101-111.   DOI   ScienceOn
18 Schoepp, D. D. (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12-20.
19 Cuadra, A. E., Kuo, S. H., Kawasaki, Y., Bredt, D. S. and Chetkovich, D. M. (2004) AMPA receptor synaptic targeting regulated by stargazin interactions with the Golgi-resident PDZ protein nPIST. J. Neurosci. 24, 7491-7502.   DOI   ScienceOn
20 Crook, J. M., Akil, M., Law, B. C., Hyde, T. M. and Kleinman, J. E. (2002) Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 7, 157-164.   DOI   ScienceOn
21 Cull-Candy, S., Brickley, S. and Farrant, M. (2001) NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11, 327-335.   DOI   ScienceOn
22 Danbolt, N. C. (2001) Glutamate uptake. Prog. Neurobiol. 65, 1-105.   DOI   ScienceOn
23 de Lucena, D., Fernandes, B. S., Berk, M., Dodd, S., Medeiros, D. W., Pedrini, M., Kunz, M., Gomes, F. A., Giglio, L. F., Lobato, M. I., Belmonte-de-Abreu, P. S. and Gama, C. S. (2009) Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 70, 1416-1423.   DOI   ScienceOn
24 De Witte, P., Littleton, J., Parot, P. and Koob, G. (2005) Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19, 517-537.   DOI   ScienceOn
25 Dev, K. K., Nishimune, A., Henley, J. M. and Nakanishi, S. (1999) The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits. Neuropharmacology 38, 635-644.   DOI   ScienceOn
26 Devon, R. S., Anderson, S., Teague, P. W., Muir, W. J, Murray, V., Pelosi, A. J., Blackwood, D. H. and Porteous, D. J. (2001) The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol. Psychiatry 6, 311-314.   DOI   ScienceOn
27 Shibata, H., Tani, A., Chikuhara, T., Kikuta, R., Sakai, M., Ninomiya, H., Tashiro, N., Iwata, N., Ozaki, N. and Fukumaki, Y. (2009) Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res. 167, 88-96.   DOI
28 Schwenk, J., Harmel, N., Zolles, G., Bildl, W., Kulik, A., Heimrich, B., Chisaka, O., Jonas, P., Schulte, U., Fakler, B. and Klocker, N. (2009) Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science 323, 1313-1319.   DOI   ScienceOn
29 Sheng, M. and Pak, D. T. (2000) Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu. Rev. Physiol. 62, 755-778.   DOI   ScienceOn
30 Shi, S., Hayashi, Y., Esteban, J. A. and Malinow, R. (2001) Subunitspecifi c rules governing AMPA receptor traffi cking to synapses in hippocampal pyramidal neurons. Cell 105, 331-343.   DOI   ScienceOn
31 Singh, S. P. and Singh, V. Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia. CNS Drugs 25, 859-885.
32 Singh, S. P. and Singh, V. (2011) Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia. CNS Drugs 25, 859-885.   DOI   ScienceOn
33 Sobolevsky, A. I., Rosconi, M. P. and Gouaux, E. (2009) X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 462, 745-756.   DOI   ScienceOn
34 Sodhi, M. S., Simmons, M., McCullumsmith, R., Haroutunian, V. and Meador-Woodruff, J. H. (2011) Glutamatergic gene expression is specifi cally reduced in thalamocortical projecting relay neurons in schizophrenia. Biol. Psychiatry 70, 646-654.   DOI   ScienceOn
35 Sokolov, B. P. (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic- free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 71, 2454-2464.
36 Dracheva, S., Marras, S. A., Elhakem, S. L., Kramer, F. R., Davis, K. L. and Haroutunian, V. (2001) N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158, 1400-1410.   DOI   ScienceOn
37 Diaz, E. (2010) Regulation of AMPA receptors by transmembrane accessory proteins. Eur. J. Neurosci. 32, 261-268.   DOI   ScienceOn
38 Dracheva, S., McGurk, S. R. and Haroutunian, V. (2005) mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 79, 868-878.   DOI   ScienceOn
39 Dracheva, S., Byne, W., Chin, B. and Haroutunian, V. (2008) Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res. 1214, 23-34.   DOI
40 Eastwood, S. L., Burnet, P. W. and Harrison, P. J. (1997a) GluR2 glutamate receptor subunit fl ip and fl op isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptasepolymerase chain reaction (RT-PCR) study. Brain Res. Mol. Brain Res. 44, 92-98.   DOI
41 Eastwood, S. L., Kerwin, R. W. and Harrison, P. J. (1997b) Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-Daspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol. Psychiatry 41, 636-643.   DOI   ScienceOn
42 Eastwood, S. L., McDonald, B., Burnet, P. W., Beckwith, J. P., Kerwin, R. W. and Harrison, P. J. (1995) Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res. Mol. Brain Res. 29, 211-223.   DOI
43 Egebjerg, J., Bettler, B., Hermans-Borgmeyer, I. and Heinemann, S. (1991) Cloning of a cDNA for a glutamate receptor subunit activated by kainate but not AMPA. Nature 351, 745-748.   DOI   ScienceOn
44 Straub, C., Hunt, D. L., Yamasaki, M., Kim, K. S., Watanabe, M., Castillo, P. E. and Tomita, S. (2011) Distinct functions of kainate receptors in the brain are determined by the auxiliary subunit Neto1. Nat. Neurosci. 14, 866-873.   DOI   ScienceOn
45 Song, I., Kamboj, S., Xia, J., Dong, H., Liao, D. and Huganir, R. L. (1998) Interaction of the N-ethylmaleimide-sensitive factor with AMPA receptors. Neuron 21, 393-400.   DOI   ScienceOn
46 Steiner, P., Alberi, S., Kulangara, K., Yersin, A., Sarria, J. C., Regulier, E., Kasas, S., Dietler, G., Muller, D., Catsicas, S. and Hirling, H. (2005) Interactions between NEEP21, GRIP1 and GluR2 regulate sorting and recycling of the glutamate receptor subunit GluR2. EMBO J 24, 2873-2884.   DOI   ScienceOn
47 Stephenson, F. A., Cousins, S. L. and Kenny, A. V. (2008) Assembly and forward traffi cking of NMDA receptors (Review). Mol. Membr. Biol. 25, 311-320.   DOI   ScienceOn
48 Takaki, H., Kikuta, R., Shibata, H., Ninomiya, H., Tashiro, N. and Fukumaki, Y. (2004) Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B, 6-14.   DOI
49 Takamori, S., Rhee, J. S., Rosenmund, C. and Jahn, R. (2000) Identification of a vesicular glutamate transporter that defi nes a glutamatergic phenotype in neurons. Nature 407, 189-194.   DOI   ScienceOn
50 Tamminga, C. (1999) Glutamatergic aspects of schizophrenia. Br. J. Psychiatry Suppl. 37, 12-15.
51 Tang, M., Pelkey, K. A., Ng, D., Ivakine, E., McBain, C. J., Salter, M. W. and McInnes, R. R. (2011) Neto1 is an auxiliary subunit of native synaptic kainate receptors. J. Neurosci. 31, 10009-10018.   DOI   ScienceOn
52 Tek, C., Srihari, V. and Tek, E. (2008) Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr. Res. 106, 373.   DOI
53 Fremeau, R. T. Jr, Burman, J., Qureshi, T., Tran, C. H., Proctor, J., Johnson, J., Zhang H., Sulzer D., Copenhagen, D. R., Storm- Mathisen, J., Reimer, R. J., Chaudhry, F. A. and Edwards, R. H. (2002) The identifi cation of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate. Proc. Natl. Acad. Sci. USA. 99, 14488-14493.   DOI   ScienceOn
54 Ehlers, M. D., Fung, E. T., O'Brien, R. J. and Huganir, R. L. (1998) Splice variant-specifi c interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci. 18, 720-730.
55 Evins, A. E., Amico, E., Posever, T. A., Toker, R. and Goff, D. C. (2002) D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56, 19-23.   DOI
56 Fell, M. J., Svensson, K. A., Johnson, B. G. and Schoepp, D. D. (2008) Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326, 209-217.   DOI   ScienceOn
57 Funk, A. J., Rumbaugh, G., Harotunian, V., McCullumsmith, R. E. and Meador-Woodruff, J. H. (2009) Decreased expression of NMDA receptor- associated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport. 20, 1019-1022.   DOI   ScienceOn
58 Galici, R., Echemendia, N. G., Rodriguez, A. L. and Conn, P. J. (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315, 1181-1187.   DOI   ScienceOn
59 Gama, C. S., Antunes, P., Moser, C. and Belmonte-de-Abreu, P. S. (2005) [Memantine as an adjunctive therapy for schizophrenia negative symptoms]. Rev. Bras. Psiquiatr. 27, 257-258.
60 Thomas, C., Carroll, B. T., Maley, R. T., Jayanti, K. and Koduri, A. (2005) Memantine and catatonic schizophrenia. Am. J. Psychiatry 162, 626.
61 Thomas, C. G., Miller, A. J. and Westbrook, G. L. (2006) Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J. Neurophysiol. 95, 1727-1734.   DOI   ScienceOn
62 Tiihonen, J., Halonen, P., Wahlbeck, K., Repo-Tiihonen, E., Hyvarinen, S., Eronen, M., Putkonen, H., Takala, P., Mehtonen, O. P., Puck, M., Oksanen, J., Koskelainen, P., Joffe, G., Aer, J., Hallikainen, T., Ryynanen, O. P. and Tupala, E. (2005) Topiramate add-on in treatment- resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychiatry 66, 1012-1015.   DOI   ScienceOn
63 Tingley, W. G., Roche, K. W., Thompson, A. K. and Huganir, R. L. (1993) Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364, 70-73.   DOI
64 Tingley, W. G., Ehlers, M. D., Kameyama, K,. Doherty, C., Ptak, J. B., Riley, C. T. and Huganir, R. L. (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-Daspartate receptor NR1 subunit using phosphorylation site-specificantibodies. J. Biol. Chem. 272, 5157-5166.   DOI
65 Tomita, S. (2010) Regulation of ionotropic glutamate receptors by their auxiliary subunits. Physiology (Bethesda) 25, 41-49.   DOI   ScienceOn
66 Toyooka, K., Iritani, S., Makifuchi, T., Shirakawa, O., Kitamura, N., Maeda, K., Nakamura, R., Niizato, K., Watanabe, M., Kakita, A., Takahashi, H., Someya, T. and Nawa, H. (2002) Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J. Neurochem. 83, 797-806.   DOI   ScienceOn
67 Tsai, G., Lane, H. Y., Yang, P., Chong, M. Y. and Lange, N. (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55, 452-456.   DOI   ScienceOn
68 Gesemann, M., Lesslauer, A., Maurer, C. M., Schonthaler, H. B. and Neuhauss, S. C. (2010) Phylogenetic analysis of the vertebrate excitatory/ neutral amino acid transporter (SLC1/EAAT) family reveals lineage specificsubfamilies. BMC Evol. Biol. 10, 117.   DOI
69 Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B. and Tamminga, C. A. (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157, 1141-1149.   DOI   ScienceOn
70 Garey, L. J., Von Bussmann, K. A. and Hirsch, S. R. (2006) Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. Exp. Brain Res. 173, 234-242.   DOI   ScienceOn
71 Ghose, S., Crook, J. M., Bartus, C. L., Sherman, T. G., Herman, M. M., Hyde, T. M., Kleinman, J. E. and Akil, M. (2008) Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int. J. Neurosci. 118, 1609-1627.   DOI   ScienceOn
72 Ghose, S., Gleason, K. A., Potts, B. W., Lewis-Amezcua, K. and Tamminga, C. A. (2009) Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatry 166, 812-820.   DOI   ScienceOn
73 Goff, D. C., Henderson, D. C., Evins, A. E. and Amico, E. (1999a) A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry. 45, 512-514.   DOI   ScienceOn
74 Goff, D. C., Herz, L., Posever, T., Shih, V., Tsai, G., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H. and Schoenfeld, D. (2005) A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179, 144-150.   DOI
75 von Engelhardt, J., Mack, V., Sprengel, R., Kavenstock, N., Li, K. W., Stern-Bach, Y., Smit, A. B., Seeburg, P. H. and Monyer, H. (2010) CKAMP44: a brain-specifi c protein attenuating short-term synaptic plasticity in the dentate gyrus. Science 327, 1518-1522.   DOI   ScienceOn
76 Tsai, G. E., Yang, P., Chang, Y. C. and Chong, M. Y. (2006) D-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 59, 230-234.   DOI   ScienceOn
77 Tsai, G., Yang, P., Chung, L. C., Lange, N. and Coyle, J. T. (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081-1089.   DOI   ScienceOn
78 Volk, D. W., Eggan, S. M. and Lewis, D. A. (2010) Alterations in metabotropic glutamate receptor 1alpha and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 167, 1489-1498.   DOI
79 Vrajova, M., Stastny, F., Horacek, J., Lochman, J., Sery, O., Pekova, S., Klaschka, J. and Hoschl, C. (2010) Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. Neurochem. Res. 35, 994-1002.   DOI   ScienceOn
80 Westphal, R. S., Tavalin, S. J., Lin, J. W., Alto, N. M., Fraser, I. D., Langeberg, L. K., Sheng, M. and Scott, J. D. (1999) Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 285, 93-96.   DOI
81 Whiteheart, S. W. and Matveeva, E. A. (2004) Multiple binding proteins suggest diverse functions for the N-ethylmaleimide sensitive factor. J. Struct. Biol. 146, 32-43.   DOI   ScienceOn
82 Woo, T. U., Shrestha, K., Amstrong, C., Minns, M. M., Walsh, J. P. and Benes, F. M. (2007) Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Schizophr. Res. 96, 46-61.   DOI   ScienceOn
83 Goff, D. C., Tsai, G., Manoach, D. S., Flood, J., Darby, D. G. and Coyle, J. T. (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry 153, 1628-1630.   DOI
84 Goff, D. C., Lamberti, J. S., Leon, A. C., Green, M. F., Miller, A. L., Patel, J., Manschreck, T., Freudenreich, O. and Johnson, S. A. (2008) A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive defi cits in schizophrenia. Neuropsychopharmacology 33, 465-472.   DOI   ScienceOn
85 Goff, D. C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A. C., Johnson, S. A. and Lynch, G. (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 21, 484-487.   DOI   ScienceOn
86 Goff, D. C, Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R. and Coyle, J. T. (1999b) A placebocontrolled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56, 21-27.   DOI   ScienceOn
87 Goff, D. C. and Wine, L. (1997) Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. 27, 157-168.   DOI
88 Gonzalez-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., Lopez-Gimenez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J. and Sealfon, S. C. (2008) Identifi cation of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97.   DOI   ScienceOn
89 Granger, A. J., Gray, J. A., Lu, W. and Nicoll, R. A. (2011) Genetic analysis of neuronal ionotropic glutamate receptor subunits. J. Physiol. 589, 4095-4101.   DOI
90 Greger, I. H. and Esteban, J. A. (2007) AMPA receptor biogenesis and traffi cking. Curr. Opin. Neurobiol. 17, 289-297.   DOI   ScienceOn
91 Gupta, D. S., McCullumsmith, R. E., Beneyto, M., Haroutunian, V., Davis, K. L. and Meador-Woodruff, J. H. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57, 123-131.   DOI   ScienceOn
92 Hashimoto, K., Fukaya, M., Qiao, X., Sakimura, K., Watanabe, M. and Kano, M. (1999) Impairment of AMPA receptor function in cerebellar granule cells of ataxic mutant mouse stargazer. J. Neurosci. 19, 6027-6036.
93 Yu, B., Wang, C., Liu, J., Johnson, K. M. and Gallagher, J. P. (2002) Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABA(A) synaptic receptors. Neuroscience 113, 1-10.   DOI   ScienceOn
94 Zavitsanou, K., Ward, P. B. and Huang X. F. (2002) Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27, 826-833.   DOI   ScienceOn
95 Zhang, W., St-Gelais, F., Grabner, C. P., Trinidad, J. C., Sumioka, A., Morimoto-Tomita, M., Kim, K. S., Straub, C., Burlingame, A. L., Howe, J. R. and Tomita, S. (2009) A transmembrane accessory subunit that modulates kainate-type glutamate receptors. Neuron 61, 385-396.   DOI   ScienceOn
96 Hammond, J. C., McCullumsmith, R. E., Funk, A. J., Haroutunian, V. and Meador-Woodruff, J. H. (2010) Evidence for abnormal forward traffi cking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 35, 2110-2119.   DOI   ScienceOn
97 Harrison, P. J., McLaughlin, D. and Kerwin, R. W. (1991) Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337, 450-452.   DOI   ScienceOn
98 Hayashi, Y., Shi, S. H., Esteban, J. A., Piccini, A., Poncer, J. C., Malinow, R. (2000) Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. Science 287, 2262-2267.   DOI   ScienceOn
99 Healy, D. J., Haroutunian, V., Powchik, P., Davidson, M., Davis, K. L., Watson, S. J. and Meador-Woodruff, J. H. (1998) AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 19, 278-286.   DOI
100 Heresco-Levy, U. and Javitt, D. C. (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 66, 89-96.   DOI   ScienceOn
101 Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S. and Ermilov, M. (2005) D-serine effi cacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry. 57, 577-585.   DOI   ScienceOn
102 Hertzmann, M., Reba, R. C. and Kotlyarov, E. V. (1990) Single photon emission computed tomography in phencyclidine and related drug abuse. Am. J. Psychiatry 147, 255-256.
103 Hollmann, M. and Heinemann, S. (1994) Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.   DOI   ScienceOn
104 Itil, T., Keskiner, A., Kiremitci, N. and Holden, J. M. (1967) Effect of phencyclidine in chronic schizophrenics. Can Psychiatr. Assoc. J. 12, 209-212.
105 Humphries, C., Mortimer, A., Hirsch, S. and de Belleroche, J. (1996) NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7, 2051-2055.   DOI   ScienceOn
106 Ibrahim, H. M., Hogg, A. J. Jr., Healy, D. J., Haroutunian, V., Davis, K. L. and Meador-Woodruff, J. H. (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry 157, 1811-1823.   DOI   ScienceOn
107 Imre, G. (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev. 13, 444-464.
108 Javitt, D. C. (2002) Glycine modulators in schizophrenia. Curr. Opin. Investig. Drugs 3, 1067-1072.
109 Javitt, D. C. (1996) Glycine therapy of schizophrenia. Biol. Psychiatry 40, 684-686.   DOI   ScienceOn
110 Javitt, D. C. (2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr. Opin. Psychiatry 19, 151-157.   DOI   ScienceOn
111 Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A. M., Bark, N., Park, M., Lindenmayer, J. P., Suckow, R. and Zukin, S. R. (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4, 385-391.
112 Javitt, D. C. and Zukin, S. R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.   DOI
113 Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco-Levy, U., Lindenmayer, J. P. (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234-1236.   DOI
114 Kalashnikova, E., Lorca, R. A., Kaur, I., Barisone, G. A., Li, B., Ishimaru, T., Trimmer, J. S., Mohapatra, D. P. and Diaz, E. (2010) SynDIG1: an activity-regulated, AMPA- receptor-interacting transmembrane protein that regulates excitatory synapse development. Neuron 65, 80-93.   DOI   ScienceOn
115 Jentsch, J. D. and Roth, R. H. (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.   DOI   ScienceOn
116 Jordan, G. R., McCulloch, J., Shahid, M., Hill, D. R., Henry, B. and Horsburgh, K. (2005) Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography. Neuropharmacology 49, 254-264.   DOI   ScienceOn
117 Joyce, J. N. and Meador-Woodruff, J. H. (1997) Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 16, 375-384.   DOI   ScienceOn
118 Kanai, Y., Smith, C. P. and Hediger, M. A. (1993) A new family of neurotransmitter transporters: the high-affi nity glutamate transporters. FASEB J. 7, 1450-1459.
119 Kanuma, K., Aoki, T. and Shimazaki, Y. (2010) Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. Recent Pat. CNS Drug Discov. 5, 23-34.
120 Kato, A. S., Gill, M. B., Yu, H., Nisenbaum, E. S. and Bredt, D. S. (2010) TARPs differentially decorate AMPA receptors to specify neuropharmacology. Trends Neurosci. 33, 241-248.   DOI   ScienceOn
121 Keifer, J. and Zheng, Z. (2010) AMPA receptor traffi cking and learning. Eur. J. Neurosci. 32, 269-277.   DOI   ScienceOn
122 Keinanen, K., Wisden, W., Sommer, B., Werner, P., Herb, A., Verdoorn, T. A., Sakmann, B. and Seeburg, P. H. (1990) A family of AMPAselective glutamate receptors. Science 249, 556-560.   DOI
123 Kristiansen, L. V., Beneyto, M., Haroutunian, V. and Meador-Woodruff, J. H. (2006) Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol. Psychiatry 11, 737-747, 705.   DOI   ScienceOn
124 Kerwin, R., Patel, S. and Meldrum, B. (1990) Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39, 25-32.   DOI   ScienceOn
125 Kessels, H. W. and Malinow, R. (2009) Synaptic AMPA receptor plasticity and behavior. Neuron 61, 340-350.   DOI   ScienceOn
126 Kornhuber, J., Bormann, J., Retz, W., Hubers, M. and Riederer, P. (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166, 589-590.   DOI   ScienceOn
127 Kristiansen, L. V., Bakir, B., Haroutunian, V. and Meador-Woodruff, J. H. (2010a) Expression of the NR2B-NMDA receptor traffi cking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr. Res. 119, 198-209.   DOI
128 Kristiansen, L. V., Patel, S. A., Haroutunian, V. and Meador-Woodruff, J. H. (2010b) Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 64, 495-502.   DOI   ScienceOn
129 Krivoy, A., Weizman, A., Laor, L., Hellinger, N., Zemishlany, Z. and Fischel, T. (2008) Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Eur. Neuropsychopharmacol. 18, 117-121.   DOI   ScienceOn
130 Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B. Jr. and Charney, D. S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.   DOI   ScienceOn
131 Lane, H. Y., Liu, Y. C., Huang, C. L., Chang, Y. C., Liau, C. H., Perng, C. H. and Tsai, G. E. (2008) Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry 63, 9-12.   DOI   ScienceOn
132 Lahti, A. C., Holcomb, H. H., Medoff, D. R. and Tamminga, C. A. (1995) Ketamine activates psychosis and alters limbic blood fl ow in schizophrenia. Neuroreport 6, 869-872.   DOI   ScienceOn
133 Lane, H. Y., Chang, Y. C., Liu, Y. C., Chiu, C. C. and Tsai, G. E. (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62, 1196-1204.   DOI   ScienceOn
134 Lane, H. Y., Lin, C. H., Huang, Y. J., Liao, C. H., Chang, Y. C. and Tsai, G. E. (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 13, 451-460.   DOI
135 Lane, H. Y., Huang, C. L., Wu, P. L., Liu, Y. C., Chang, Y. C., Lin, P. Y., Chen, P. W. and Tsai, G. (2006) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60, 645-649.   DOI   ScienceOn
136 Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L. and Innis, R. (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46, 56-72.   DOI   ScienceOn
137 Lau, C. G. and Zukin, R. S. (2007) NMDA receptor traffi cking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8, 413-426.
138 Lavezzari, G., McCallum, J., Dewey, C. M. and Roche, K. W. (2004) Subunit-specifi c regulation of NMDA receptor endocytosis. J. Neurosci. 24, 6383-6391.   DOI   ScienceOn
139 Le Corre, S., Harper, C. G., Lopez, P., Ward, P. and Catts, S. (2000) Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 11, 983-986.   DOI   ScienceOn
140 Lehre, K. P., Levy, L. M., Ottersen, O. P., Storm-Mathisen, J. and Danbolt, N. C. (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 15, 1835-1853.
141 Lerma, J. (2003) Roles and rules of kainate receptors in synaptic transmission. Nat. Rev. Neurosci. 4, 481-495.   DOI   ScienceOn
142 Letts, V. A, Felix, R., Biddlecome, G. H., Arikkath, J., Mahaffey, C. L., Valenzuela, A., Bartlett, F. S., 2nd, Mori, Y., Campbell, K. P. and Frankel, W. N. (1998) The mouse stargazer gene encodes a neuronal $Ca^{2+}$-channel gamma subunit. Nat. Genet. 19, 340-347.   DOI   ScienceOn
143 Li, D., Specht, C. G., Waites, C. L., Butler-Munro, C., Leal-Ortiz, S., Foote, J. W., Genoux, D., Garner, C. C. and Montgomery, J. M. (2011) SAP97 directs NMDA receptor spine targeting and synaptic plasticity. J. Physiol. 589, 4491-4510.   DOI
144 Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D. and Gage, A. (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34, 1322-1329.   DOI   ScienceOn
145 Lin, J. W., Wyszynski, M., Madhavan, R., Sealock, R., Kim, J. U. and Sheng, M. (1998) Yotiao, a novel protein of neuromuscular junction and brain that interacts with specifi c splice variants of NMDA receptor subunit NR1. J. Neurosci. 18, 2017-2027.
146 Lu, W. and Ziff, E. B. (2005) PICK1 interacts with ABP/GRIP to regulate AMPA receptor traffi cking. Neuron. 47, 407-421.   DOI   ScienceOn
147 Mah, S. J., Cornell, E., Mitchell, N. A. and Fleck, M. W. (2005) Glutamate receptor traffi cking: endoplasmic reticulum quality control involves ligand binding and receptor function. J. Neurosci. 25, 2215-2225.   DOI   ScienceOn
148 Malinow, R. and Malenka, R. C. (2002) AMPA receptor traffi cking and synaptic plasticity. Annu. Rev. Neurosci. 25, 103-126.   DOI   ScienceOn
149 Aihara, Y., Mashima, H., Onda, H., Hisano, S., Kasuya, H., Hori, T., Yamada, S., Tomura, H., Yamada, Y., Inoue, I., Kojima, I. and Takeda, J. (2000) Molecular cloning of a novel brain-type Na(+)-dependent inorganic phosphate cotransporter. J. Neurochem. 74, 2622-2625.
150 Aanonsen, L. M. and Wilcox, G. L. (1986) Phencyclidine selectively blocks a spinal action of N-methyl-D-aspartate in mice. Neurosci. Lett. 67, 191-197.   DOI   ScienceOn
151 Akbarian, S., Sucher, N. J., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W. P., Potkin, S. G., Sandman, C. A., Bunney, W. E. Jr. and Jones, E. G. (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16, 19-30.
152 Anggono, V., Clem, R. L. and Huganir, R. L. (2011) PICK1 loss of function occludes homeostatic synaptic scaling. J. Neurosci. 31, 2188-2196.   DOI   ScienceOn
153 Arai, A., Kessler, M., Rogers, G. and Lynch G. (1996) Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J. Pharmacol. Exp. Ther. 278, 627-638.
154 Meador-Woodruff, J. H., Hogg, A. J. Jr. and Smith, R. E. (2001b) Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 55, 631-640.   DOI   ScienceOn
155 Masson, J., Sagne, C., Hamon, M. and El Mestikawy, S. (1999) Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51, 439-464.
156 McCullumsmith, R. E., Kristiansen, L. V., Beneyto, M., Scarr, E., Dean, B. and Meador-Woodruff J. H. (2007) Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 1127, 108-118.   DOI
157 Meador-Woodruff, J. H., Davis, K. L. and Haroutunian, V. (2001a) Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 24, 545-552.   DOI   ScienceOn
158 Milton, I. D., Banner, S. J., Ince, P. G., Piggott, N. H., Fray, A. E., Thatcher, N., Horne, C. H. and Shaw, P. J. (1997) Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res. Mol. Brain Res. 52, 17-31.   DOI
159 Mirnics, K., Middleton, F. A., Marquez, A., Lewis, D. A. and Levitt, P. (2000) Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67.   DOI   ScienceOn
160 Moghaddam, B. and Adams, B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352.   DOI
161 Moghaddam, B., Adams, B., Verma, A. and Daly, D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921-2927.
162 Bats, C., Groc, L. and Choquet, D. (2007) The interaction between Stargazin and PSD-95 regulates AMPA receptor surface traffi cking. Neuron 53, 719-734.   DOI   ScienceOn
163 Araque, A., Parpura V., Sanzgiri R. P. and Haydon P. G. (1999) Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22, 208-215.   DOI   ScienceOn
164 Arvanov, V. L. and Wang, R. Y. (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Ther. 289, 1000-1006.
165 Bar-Peled, O., Ben-Hur, H., Biegon, A., Groner, Y., Dewhurst, S., Furuta, A. and Rothstein J. D. (1997) Distribution of glutamate transporter subtypes during human brain development. J. Neurochem. 69, 2571-2580.
166 Bellocchio, E. E., Reimer, R. J., Fremeau, R. T. Jr. and Edwards, R. H. (2000) Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289, 957-960.   DOI
167 Benes, F. M., Todtenkopf, M. S. and Kostoulakos, P. (2001) GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus 11, 482-491.   DOI   ScienceOn
168 Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E. and Meador-Woodruff J. H. (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32, 1888-1902.   DOI   ScienceOn
169 Beneyto, M. and Meador-Woodruff, J. H. (2006) Lamina-specifi c abnormalities of AMPA receptor traffi cking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60, 585-598.   DOI   ScienceOn
170 Beneyto, M. and Meador-Woodruff, J. H. (2008) Lamina-specifi c abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33, 2175-2186.   DOI   ScienceOn
171 Nagao, S., Kwak, S. and Kanazawa, I. (1997) EAAT4, a glutamate transporter with properties of a chloride channel, is predominantly localized in Purkinje cell dendrites, and forms parasagittal compartments in rat cerebellum. Neuroscience 78, 929-933.   DOI   ScienceOn
172 Mueller, H. T., Haroutunian, V., Davis, K. L. and Meador-Woodruff, J. H. (2004) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res. Mol. Brain Res. 121, 60-69.   DOI
173 Mueller, H. T. and Meador-Woodruff, J. H. (2004) NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr. Res. 71, 361-370.   DOI   ScienceOn
174 Naassila, M., Hammoumi, S., Legrand, E., Durbin, P. and Daoust, M. (1998) Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol. Clin. Exp. Res. 22, 802-809.   DOI   ScienceOn
175 Neuhauss, S. C., Rico, E. P. and Gesemann, M. (2010) Nomenclature of glutamate transporters in zebrafi sh and other vertebrates. Brain Res. Bull. 83, 297.   DOI   ScienceOn
176 Newell, K. A., Zavitsanou, K. and Huang, X. F. (2005) Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport 16, 1363-1367.   DOI   ScienceOn
177 Ng, D., Pitcher, G. M., Szilard, R. K., Sertie, A., Kanisek, M., Clapcote, S. J., Lipina, T., Kalia, L. V., Joo, D., McKerlie, C., Cortez, M., Roder, J. C., Salter, M. W. and McInnes, R. R. (2009) Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. PLoS Biol. 7, e41.   DOI
178 Ni, Y., Malarkey, E. B. and Parpura, V. (2007) Vesicular release of glutamate mediates bidirectional signaling between astrocytes and neurons. J. Neurochem. 103, 1273-1284.   DOI   ScienceOn
179 Bettler, B., Boulter, J., Hermans-Borgmeyer, I., O'Shea-Greenfi eld, A., Deneris, E. S., Moll, C., Borgmeyer, U., Hollmann, M. and Heinemann, S. (1990) Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron 5, 583-595.   DOI   ScienceOn
180 Bergeron, R., Meyer, T. M., Coyle, J. T. and Greene, R.W. (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. USA. 95, 15730-15734.   DOI   ScienceOn
181 Bleakman, D. and Lodge, D. (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37, 1187-1204.   DOI   ScienceOn
182 Boulter, J., Hollmann, M., O'Shea-Greenfi eld, A., Hartley, M., Deneris, E., Maron, C. and Heinemann, S. (1990) Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249, 1033-1037.   DOI
183 Bredt, D. S. and Nicoll, R. A. (2003) AMPA receptor traffi cking at excitatory synapses. Neuron 40, 361-379.   DOI   ScienceOn
184 Breese, C. R., Freedman, R. and Leonard, S. S. (1995) Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674, 82-90.   DOI   ScienceOn
185 Buchanan, R. W. and Carpenter, W. T. (2000) Schizophrenia: Introduction and Overview. In Comprehensive Textbook of Psychiatry, 7th Edition (B. J. Sadock, V. A. Sadock, Eds), pp. 1096-1110. Lippincott, Williams, and Wilkins, Philadelphia.
186 Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U. and Carpenter, W. T. (2007) The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the effi cacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593-1602.   DOI   ScienceOn
187 Carpenter, S. S., Hatchett, A. D. and Fuller, M. A. (2006) Catatonic schizophrenia and the use of memantine. Ann. Pharmacother. 40, 344-346.   DOI   ScienceOn
188 Noga, J. T., Hyde, T. M., Herman, M. M., Spurney, C. F., Bigelow, L. B., Weinberger, D. R. and Kleinman, J. E. (1997) Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 27, 168-176.   DOI   ScienceOn
189 Nishikawa, T., Takashima, M. and Toru, M. (1983) Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci. Lett. 40, 245-250.   DOI   ScienceOn
190 Noebels, J. L., Qiao, X., Bronson, R. T., Spencer, C. and Davisson, M. T. (1990) Stargazer: a new neurological mutant on chromosome 15 in the mouse with prolonged cortical seizures. Epilepsy. Res. 7, 129-135.   DOI   ScienceOn
191 Noga, J. T. and Wang, H. (2002) Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 45, 250-258.   DOI   ScienceOn
192 Noorbala, A. A., Akhondzadeh, S., Davari-Ashtiani, R. and Amini- Nooshabadi, H. (1999) Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J. Clin. Pharm. Ther. 24, 369-374.   DOI   ScienceOn
193 Ohnuma, T., Augood, S. J., Arai, H., McKenna, P. J. and Emson, P. C. (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res. Mol. Brain Res. 56, 207-217.   DOI
194 Ohtsuki, T., Toru, M. and Arinami, T. (2001) Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr. Genet. 11, 79-83.   DOI   ScienceOn
195 Olive, M. F. (2009) Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr. Drug Abuse. Rev. 2, 83-98.   DOI   ScienceOn
196 Paz, R. D., Tardito, S., Atzori, M. and Tseng, K. Y. (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur. Neuropsychopharmacol. 18, 773-786.   DOI   ScienceOn
197 Chen, L., El-Husseini, A., Tomita, S., Bredt, D. S. and Nicoll, R. A. (2003) Stargazin differentially controls the traffi cking of alpha-amino- 3-hydroxyl-5-methyl-4-isoxazolepropionate and kainate receptors. Mol. Pharmacol. 64, 703-706.   DOI   ScienceOn
198 Carroll, B. T., Thomas, C. and Jayanti, K. (2006) Amantadine and memantine in catatonic schizophrenia. Ann. Clin. Psychiatry. 18, 133-134.   DOI   ScienceOn
199 Chaki, S. (2010) Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur. J. Pharmacol. 639, 59-66.   DOI
200 Chaki, S. and Hikichi, H. (2011) Targeting of metabotropic glutamate receptors for the treatment of schizophrenia. Curr. Pharm. Des. 17, 94-102.   DOI   ScienceOn
201 Chen, L., Chetkovich, D. M., Petralia, R. S., Sweeney, N. T., Kawasaki, Y., Wenthold, R. J., Bredt, D. S. and Nicoll, R. A. (2000) Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature 408, 936-943.   DOI   ScienceOn
202 Chung, H. J., Huang, Y. H., Lau, L. F. and Huganir, R. L. (2004) Regulation of the NMDA receptor complex and traffi cking by activitydependent phosphorylation of the NR2B subunit PDZ ligand. J. Neurosci. 24, 10248-10259.   DOI   ScienceOn
203 Citri, A., Bhattacharyya, S., Ma, C., Morishita, W., Fang, S., Rizo, J. and Malenka, R. C. (2010) Calcium binding to PICK1 is essential for the intracellular retention of AMPA receptors underlying longterm depression. J. Neurosci. 30, 16437-16452.   DOI   ScienceOn
204 Clem, R. L., Anggono, V. and Huganir, R. L. (2010) PICK1 regulates incorporation of calcium-permeable AMPA receptors during cortical synaptic strengthening. J. Neurosci. 30, 6360-6366.   DOI   ScienceOn
205 Clinton, S. M., Haroutunian, V., Davis, K. L. and Meador-Woodruff J. H. (2003) Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 160, 1100-1109.   DOI   ScienceOn
206 Ralevski, E., O'Brien, E., Jane, J. S., Dean, E., Dwan, R. and Petrakis, I. (2011) Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J. Nerv. Ment. Dis. 199, 499-505.   DOI   ScienceOn
207 Porter, R. H., Eastwood, S. L. and Harrison, P. J. (1997) Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751, 217-231.   DOI   ScienceOn
208 Prybylowski, K., Chang, K., Sans, N. and Kan, L., Vicini S., Wenthold R. J. (2005) The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 47, 845-857.   DOI   ScienceOn
209 Ratnam, J. and Teichberg, V. I. (2005) Neurofi lament-light increases the cell surface expression of the N-methyl-D-aspartate receptor and prevents its ubiquitination. J. Neurochem. 92, 878-885.   DOI   ScienceOn
210 Rao, A. and Craig, A. M. (1997) Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. Neuron 19, 801-812.   DOI   ScienceOn
211 Richardson-Burns, S. M., Haroutunian, V., Davis, K. L., Watson, S. J. and Meador-Woodruff, J. H. (2000) Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry 47, 22-28.   DOI   ScienceOn
212 Rico, E. P., de Oliveira, D. L., Rosemberg, D. B., Mussulini, B. H., Bonan, C. D., Dias, R. D., Wofchuk, S., Souza, D. O. and Bogo, M. R. (2010) Expression and functional analysis of Na(+)-dependent glutamate transporters from zebrafi sh brain. Brain Res. Bull. 81, 517-523.   DOI   ScienceOn
213 Rosse, R. B., Schwartz, B. L., Davis, R. E. and Deutsch, S. I. (1991) An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin. Neuropharmacol. 14, 268-272.   DOI   ScienceOn